Mikrovaskularna gustina u iglenim biopsijama prostate - prediktor prognoze?
Sažetak
Cilj. Cilj našeg rada je ispitivanje mikrovaskularne gustine (MVD) u core biopsijama karcinoma prostate (PC).
Metoda. Na core biopsijama PC (n=25 ) i benigne hiperplazije prostate(BHP), served as controls (n=20) su, nakon rutinske obrade, primenjene klasična HE i imunohistohemijska ABC metoda sa CD105 antitelima. Svi ispitanici su imali nivo serumskog PSA >4.0 ng/mL. Srednja vrednost volumena prostate je 50.02, prosečan Gleason score je 7.7. MVD se računala brojanjem CD105 pozitivnih struktura u 5 „vrućih tačaka“. Nakon kvantitativne analize, stereometrijski je izračunata MVD po mm2. .Za statističku obradu dobijenih rezultata korišćen je programski paket SPSS (verzija 19.0).
Rezultati. Srednja vrednost CD 105 pozitivnih ćelija po mm2 je značajno veća u PC nego kod BHP (676.6 vs 186.5). U PC postoji signifikantna povezanost MVD sa Gleason score (r=0.831) i nivoom PSA (r=0.343). Između PSA i volumena prostate postoji umerena pozitivna povezanost (r=0.565).
Zaključak. Vrednost MVD indeksa moze biti značajan indikator progresije karcinoma prostate, tako da je moguće razlikovati pacijente kod kojih je ovaj rizik veći.
Ključne reči: rak prostate, mikrovaskularna gustina, core biopsija, povećan rizik, progresija
Reference
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al.Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. European Journal of Cancer 2013;( 49): 1374-1403.
Feletto E., Bang A., Cole-Clark D., Chalasani V., Rasiah K., Smith D.P. An examination of prostate cancer trends in Australia, England, Canada and USA: is the Australian death rate too high? World J Urol. 2015; (33): 1677–1687.
Leitzmann MF, Rohrmann S. Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates. Clin Epidemiol. 2012; (4): 1–11
Bray F., Jemal A., Grey N., Ferlay J., Forman D. Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. Lancet Oncol. 2012; 13: 790–801
Di Sebastiano KM, Mourtzakis M. The Role of Dietary Fat throughout the Prostate Cancer Trajectory.Nutrients. 2014; 6(12): 6095-6109
Drake I, Sonestedt E, Gullberg B, Ahlgren G, Bjartell A, Wallström P et al. Dietary intakes of carbohydrates in relation to prostate cancer risk: a prospective study in the Malmö Diet and Cancer cohort.Am J Clin Nutr. 2012; 96(6): 1409-1418.
Catalona, William J. "Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men."The Journal of urology 2017; (197): S200-S207.
Tyloch JF, Wieczorek AP. The standards of an ultrasound examination of the prostate gland. Part 1. Journal of Ultrasonography. 2016; 16 (67): 378-390.
Dell'Atti L. Can transrectal ultrasound-guided biopsy of the prostate with extended 14-core scheme improve the predictive accuracy of Gleason score and tumor site in prostate cancer treatment?J BUON. 2015; 20(5): 1239-1243.
Romero D, O’Neill C, Terzic A. Endoglin regulates cancer-stromal cell interactions in prostate tumors. Cancer research. 2011; 71(10): 3482-3493
Miyata, Yasuyoshi, et al. "Pathological significance and prognostic role of microvessel density, evaluated using CD31, CD34, and CD105 in prostate cancer patients after radical prostatectomy with neoadjuvant therapy." The Prostate 2015; (75): 84-91
Ferlay JSI, Ervik M, Dikshit R, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer, 2013.
Ji G, Huang C, Song G, et al. Are the Pathological Characteristics of Prostate Cancer More Aggressive or More Indolent Depending upon the Patient Age? BioMed Research International. 2017;1438027
Lopez-Novoa JM, Bernabeu C ."ENG (endoglin)". Atlas of Genetics and Cytogenetics in Oncology and Haematology.
Altomonte M, Montagner R, Fonsatti E et al. "Expression and structural features of endoglin (CD105), a transforming growth factor beta1 and beta3 binding protein, in human melanoma". British Journal of Cancer.1996; (10): 1586–1591.
Saad RS, Jasnosz KM, Silverman JF. Endoglin (CD105) expression in endometrial carcinoma. Int J Gynecol Pathol, 2003; (22): 248-253
Coston WMP, Loera S, Lau SK, et al. Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry. Am J Surg Pathol 2008; (32) : 433-44.
Łuczyńska E, Gasińska A, Wilk W. Microvessel density and expression of vascular endothelial growth factor in clinically localized prostate cancer. Pol J Pathol. 2013; ( 1): 33-38
Erbersdobler A, Isbarn H, Dix K, et al. Prognostic value of microvessel density in prostate cancer: a tissue microarray study. World J Urol 2010; (28): 687-692
Lau WK, Bergstralh EJ, Blute ML,Slezak JM, Zincke H. Radical prostatectomy for pathological Gleason 8 orgreater prostate cancer: influence of concomitant pathological variables. J Urol, 2002;(167): 117-122
EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer, Heidenreich, Axel et al.European Urology 2011; (2): 467 – 479
Klein EA, Platz EA, Thompson IM. Epidemiology, etiology and prevention of prostate cancer. In: Kavoussi LR, Novic AC, Partin AW, Peters CA, eds. Campbell-Walsh Urology. Philadelphia: Saunders; 2007. pp.2854-2873.
G Di Lorenzol, S. De Plasidol, R Autorino, M De Laurentiis, C Mignoga, M D Armiento et al. Expression of biomarkers modulating prostate cancer progression: implication in the tretmentof the disease.Prostate Cancer and Prostate Disease. 2005; (8): 54-59.